6,678 trials
Alzheimer's Disease
Primary: Percentage of Patients Who Achieved and Maintained the Maximum Dose of 10 cm^2 Rivastigmine Patch for at Least 8 Weeks During 24 Weeks Study — 70.6 Percentage of…
Skin Manifestations
Primary: Number of Participants Who Were a Success With Regard to Worst Post-baseline Tolerability Assessment Scores in Each Assessment (Erythema, Scaling, Dryness…
Skin Manifestations
Primary: Number of Participants Who Were a Success With Regard to Worst Post-baseline Tolerability Scores in Each Assessment (Erythema, Scaling, Dryness, Stinging/Burning) From…
Asthma · Acute Asthma · Reactive Airway Exacerbation
Primary: Median Change in Asthma Score 2 Hours After Intervention — -3; -3 Units on a scale — p=0.44
Fatigue
Primary: Participants Considered "Responders" (Scored 1 or 2) on Clinical Global Impressions Scale — 19; 1 participants considered "responders"
Asthma
Primary: Persistency of Response and Non-response as Based on Investigator's Global Evaluation of Treatment Effectiveness (GETE) — 190; 29; 187; 28 participants
Growth Hormone Deficiency
Primary: Subject-reported Injection Anxiety Immediately Before Administration — 2.15; 1.98 Scores on a scale
Hypertension
Primary: Change in 24 Hour (24-Hr) Mean Ambulatory Systolic Blood Pressure (MASBP) From the End of the Active Treatment Period to Day 7 of the Withdrawal Period — 2.70; 6.51 mmHg
Hemorrhoids · Pain
Primary: NRS Pain = Numeric Rating Scale (0-10) — 1.6; 1.5 Units on a scale — p=>0.05
Intervertebral Disk Displacement · Disk Prolapse
Primary: Mean VAS Pain (Visual Analogue Scale)at Rest (0-100 mm) — 11.7; 22.5 Units on a scale
Non-diabetic Nephropathy With Hypertension
Primary: The Change in Urinary Protein/Creatinine Ratio From Baseline to 28 Weeks — 794.0; 639.9; 819.0 mg/g
Hypercholesteremia
Primary: Percent Change From Baseline (Before the Start of Rosuvastatin Treatment) to Week 76 in the Plaque Volume (PV) — 14.1 Percent Change
Anemia · Neoplasms
Primary: Number of Participants With at Least 1 Clinically Relevant and Objectively Confirmed Thrombovascular Event From Randomization Through Week 16 — 5; 10 particpants — p=0.248
Healthy
Primary: High VAS - Emax (mm) — 23.1; 30.6; 62.5; 81.4 mm — p=<0.001
Healthy
Primary: Percentage of Participants Reporting Fever, Defined as Oral Temperature ≥ 101°F — 0.4; 0.0 Percentage of participants